Torben Straight Nissen Net Worth

The estimated Net Worth of Torben Straight Nissen is at least $9.69 Milione dollars as of 24 July 2019. Torben Nissen owns over 207,146 units of Axcella Health Inc stock worth over $9,400,221 and over the last 6 years Torben sold AXLA stock worth over $293,920.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Torben Nissen AXLA stock SEC Form 4 insiders trading

Torben has made over 3 trades of the Axcella Health Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Torben exercised 207,146 units of AXLA stock worth $37,286 on 24 July 2019.

The largest trade Torben's ever made was exercising 207,146 units of Axcella Health Inc stock on 24 July 2019 worth over $37,286. On average, Torben trades about 44,368 units every 22 days since 2019. As of 24 July 2019 Torben still owns at least 2,052,450 units of Axcella Health Inc stock.

You can see the complete history of Torben Nissen stock trades at the bottom of the page.

What's Torben Nissen's mailing address?

Torben's mailing address filed with the SEC is C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.

Insiders trading at Axcella Health Inc

Over the last 6 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa... e Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.

What does Axcella Health Inc do?

axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.

Complete history of Torben Nissen stock trades at Rubius Therapeutics Inc e Axcella Health Inc

Axcella Health Inc executives and stock owners

Axcella Health Inc executives and other stock owners filed with the SEC include:

• Shreeram Aradhye,
  Executive Vice President, Chief Development Officer
• Manu Chakravarthy,
  Senior Vice President, Chief Medical Officer
• William Hinshaw,
  President, Chief Executive Officer, Director
• David Epstein,
  Chairman of the Board
• William R. Hinshaw Jr.,
  Pres, CEO & Director
• Laurent Chardonnet,
  Consultant
• William Baird,
  Independent Director
• Catherine Sohn,
  Independent Director
• Gary Pisano,
  Independent Director
• Gregory Behar,
  Independent Director
• Cristina Rondinone,
  Independent Director
• Stephen Hoge,
  Independent Director
• Stephen Mitchener,
  Senior Vice President, Chief Business Officer
• Paul Fehlner,
  Senior Vice President, Chief Intellectual Property Officer
• Heidy King-Jones,
  Senior Vice President of Legal, General Counsel
• Tony Tramontin,
  Senior Vice President of Research and Development , Chief Scientific Officer
• Laurent Chardonnet,
  Chief Financial Officer, Senior Vice President
• Karim Azer Ph.D.,
  VP of Systems Biology & Discovery
• Dr. Margaret Koziel M.D.,
  Sr. VP & Chief Medical Officer
• Dr. Alison D. Schecter M.D.,
  Pres of R&D
• Dr. Larry Bell,
  Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP
• Virginia R. Dean,
  Sr. VP & Chief People Officer
• Dr. Paul Fehlner J.D., Ph.D.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Jason Fredette,
  VP of Investor Relations & Corp. Communications
• Health Science Us Holdings,...,
  
• Michael Rosenblatt,
  Director
• David A Berry,
  Director
• Ventures Fund Iv General Pa...,
  
• Paul J Sekhri,
  Director
• Ventures Fund Iv General Pa...,
  
• Des Produits Nestle S.A.Nes...,
  
• Alison D. Schecter,
  President - Research & Dev.
• Virginia R Dean,
  SVP, Chief People Officer
• Margaret Koziel,
  Chief Medical Officer
• Ventures Fund Iv General Pa...,
  
• Robert Crane,
  Chief Financial Officer
• Torben Straight Nissen,
  Director
• Robert L. Rosiello,
  Director